Publications by authors named "Dylan Sherry"
Background: Opioids remain the cornerstone for the treatment of moderate to severe cancer pain. Due to benefits over full agonist opioids (FAO), buprenorphine has emerged as an alternative treatment.
Purpose/hypothesis: Buprenorphine is only approved for the treatment of pain that is chronic non-cancer.
Context: Medical cannabis is increasingly considered for palliation of pain, nausea/vomiting, anorexia, and other symptoms.
Objectives: We aimed to determine whether training in hospice and palliative medicine (HPM) adequately prepares fellows to counsel patients about medical cannabis.
Methods: A previously validated questionnaire was adapted for HPM fellows.
Article Synopsis
- Cancer pain is a big issue for many people undergoing treatment, especially those with worse stages of the disease.
- Doctors usually use opioids like morphine to help manage this pain, but a newer option called buprenorphine is being considered.
- Experts think buprenorphine could be a good first choice for some patients, especially the elderly or those with kidney problems, but more research is needed to be sure.
Advance care planning (ACP) is important to improving end-of-life care. Few studies have examined the impact of primary care physician (PCP) involvement in ACP. To determine whether complete ACP, defined as health care proxy (HCP), provider orders for life-sustaining treatment (POLST), and documented goals-of-care (GOC) conversations, would occur earlier when the PCP was involved in POLST and/or GOC conversations.
View Article and Find Full Text PDF